Document ID: FDA-2022-N-0621-0001
Agency: fda
Document Type: Notice
Title: Advisory Committee; Anesthetic and Analgesic Drug Products Advisory Committee; Renewal
Posted Date: 2022-05-05T04:00Z

[Federal Register Volume 87, Number 87 (Thursday, May 5, 2022)]
[Notices]
[Pages 26762-26763]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-09610]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-N-0621]

Advisory Committee; Anesthetic and Analgesic Drug Products 
Advisory Committee; Renewal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; renewal of Federal advisory committee.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the

[[Page 26763]]

renewal of the Anesthetic and Analgesic Drug Products Advisory 
Committee by the Commissioner of Food and Drugs (the Commissioner). The 
Commissioner has determined that it is in the public interest to renew 
the Anesthetic and Analgesic Drug Products Advisory Committee for an 
additional 2 years beyond the charter expiration date. The new charter 
will be in effect until the May 1, 2024, expiration date.

DATES: Authority for the Anesthetic and Analgesic Drug Products 
Advisory Committee will expire on May 1, 2024, unless the Commissioner 
formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Moon Hee V. Choi, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-2894, [email protected].

SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by 
the Department of Health and Human Services and by the General Services 
Administration, FDA is announcing the renewal of the Anesthetic and 
Analgesic Drug Products Advisory Committee (the Committee). The 
Committee is a discretionary Federal advisory committee established to 
provide advice to the Commissioner. The Committee advises the 
Commissioner or designee in discharging responsibilities as they relate 
to helping to ensure safe and effective drugs for human use and, as 
required, any other product for which FDA has regulatory 
responsibility.
    The Committee reviews and evaluates available data concerning the 
safety and effectiveness of marketed and investigational human drug 
products including analgesics, e.g., abuse-deterrent opioids, novel 
analgesics, and issues related to opioid abuse, and those for use in 
anesthesiology and makes appropriate recommendations to the 
Commissioner of Food and Drugs.
    The Committee shall consist of a core of 11 voting members 
including the Chair. Members and the Chair are selected by the 
Commissioner or designee from among authorities knowledgeable in the 
fields of anesthesiology, analgesics (such as: Abuse deterrent opioids, 
novel analgesics, and issues related to opioid abuse), epidemiology or 
statistics, and related specialties. Members will be invited to serve 
for overlapping terms of up to 4 years. Non-federal members of the 
committee will serve as Special Government Employees, representatives 
or Ex-Officio members. Federal members will serve as Regular Government 
Employees or Ex-Officios. The core of voting members may include one 
technically qualified member, selected by the Commissioner or designee, 
who is identified with consumer interests and is recommended by either 
a consortium of consumer-oriented organizations or other interested 
persons. In addition to the voting members, the Committee may include 
one non-voting representative member who is identified with industry 
interests. There may also be an alternate industry representative.
    Further information regarding the most recent charter and other 
information can be found at https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/anesthetic-and-analgesic-drug-products-advisory-committee-charter or by contacting 
the Designated Federal Officer (see FOR FURTHER INFORMATION CONTACT). 
In light of the fact that no change has been made to the committee name 
or description of duties, no amendment will be made to 21 CFR 14.100.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app.). For general information related to FDA advisory 
committees, please visit us at http://www.fda.gov/AdvisoryCommittees/default.htm.

    Dated: April 29, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-09610 Filed 5-4-22; 8:45 am]
BILLING CODE 4164-01-P